Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.
Nasopharyngeal Carcinoma
DRUG: Toripalimab|RADIATION: Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation
Induction chemotherapy completion rate, Induction chemotherapy completion rate, defined as the proportion of patients who complete three cycles of chemoimmunotherapy within 12 weeks of initiation. Completion is defined for induction as receiving all 3 cycles as planned, including protocol specified dose reduction and delays. ., 3 years|Radiation completion rate, Radiation completion rate, defined as the proportion of patients who complete specified radiation within 8 weeks of radiation initiation. Radiation completion is defined as completion of planned doses of radiation., 3 years
Overall Response (ORD) rate following induction, OR rate following induction, defined as the proportion of patients who achieve at least a RECIST defined PR within 12 weeks of induction chemotherapy initiation., 3 years|Complete Response (CR) rate following radiation, CR rate following radiation, defined as the proportion of patients who achieve a RECIST defined CR within 16 weeks following the end of radiation therapy., 3 years
The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.